Navigation Links
Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
Date:10/6/2011

PHILADELPHIA, Oct. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical study of its Symphony tCGM System.  Data from the study confirm that Symphony successfully monitors patient glucose levels and continues to demonstrate improvements in clinical performance.  Echo plans to conduct a study in patients with diabetes during the fourth quarter, followed by a study in critical care patients shortly thereafter.

"The results of this study demonstrate that this next generation of Symphony successfully monitors glucose levels and has the potential to be an important tool for tracking and trending of glucose.  The adoption of CGM is growing rapidly in diabetes management, as is frequent glucose testing in critical care patients, as medical literature continues to underscore the need for better glucose control to improve patient outcomes," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We are excited about these results and the potential for Symphony and we expect similar, positive results from the two additional studies in diabetics and critical care patients in the coming months."

Study Design

The feasibility study was designed to evaluate the performance of the Symphony tCGM System.  Twelve (12) adult subjects, each without a history of diabetes, were evaluated.  The skin of each subject was prepared using Prelude and a Symphony tCGM biosensor was applied to the skin site.  Venous reference blood samples were taken from intravenous lines at 15-minute intervals for 24 hours and measured on a YSI 2300 STAT Plus Glucose Analyzer and a commercially available, professional-use glucometer.  The study data was blinded to study subjects and study personnel. At the conclusion of the 24-hour study period, the test skin sites were inspected for redness or other undesirable effects.

Analytical Methods

Continuous data from the Symphony tCGM System were compared to reference measurements from a YSI 2300 STAT Plus Glucose Analyzer and professional-use blood glucose test system.  Those reference measurements were paired with the Symphony results through a data analysis algorithm.  The primary statistical analysis tools used to evaluate the performance of Symphony were the Continuous Glucose-Error Grid analysis (CG-EGA) and Mean Absolute Relative Difference (MARD).  The CG-EGA is a categorization of all data pairs based on the clinical significance of the accuracy. Accurate readings result in the same clinical decision when based on the CGM value versus the blood glucose value. Benign errors lead to the same clinical outcome as accurate readings even though the actual clinical decision may differ. Erroneous readings lead to clinical errors. CGM performance is measured as the sum of accurate readings and benign errors.  Numerical accuracy is measured using MARD, an error calculation tool that was used to measure the absolute value of the average relative difference between Symphony and the reference measurements, on a percentage basis.

Study Results

Using over 1,600 Symphony tCGM glucose readings from the 12 study subjects paired with reference blood glucose measurements, CG-EGA showed that 98.3% of the readings were clinically accurate and 1.2% were benign errors with a combined A+B of 99.5%. The MARD for the study was 10.5%.  Values for blood glucose measurements ranged from 64 to 212 mg/dL. There were no adverse events reported from the Prelude skin permeation or the Symphony tCGM biosensor.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including: the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems; the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems; Echo's ability to secure additional commercial partnering arrangements; risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems; the availability of substantial additional funding to support its research, development and product commercialization activities; and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Forms 10-Q, and its Current Reports on Forms 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
2. Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
3. Argos Therapeutics Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
4. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
5. Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
6. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
7. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
8. Pearl Therapeutics Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
9. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
10. Afraxis Enters Collaboration with NIH as Part of Therapeutics for Rare and Neglected Disease Program
11. Reed V. Tuckson, M.D., Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)...   Hudes Laser Aesthetica announced their ... Astanza Trinity laser and Astanza Liberty IPL technologies. ... removal, IPL hair removal, pigmented and vascular lesion ... Aesthetica is setting high standards for aesthetic clinics ... to deliver effective, long-lasting results. "Hudes ...
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 ... Optical Transceiver Market 2016-2020" report to their offering. ... The report forecasts the ... during the period 2016-2020. The report covers the ... market for 2016-2020. To calculate the market size, the report considers ...
(Date:12/9/2016)... LLC announced today that Steven E. Dawson has been appointed as chief ... Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing and executing transformation, ... brings to the company deep operational and leadership expertise, a strong financial ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... 2016 , ... Holiday shopping, decorating, parties, family gatherings, and ... that can put a great deal of stress on consumers this and every ... food and festive gatherings can lead to excessive behaviors, which has an impact ...
(Date:12/10/2016)... ... December 10, 2016 , ... The ... PATS recently joined forces with other healthcare organizations to promote diabetes education at ... in Harrisburg, featured a variety of speakers from around the Commonwealth of Pennsylvania. ...
(Date:12/10/2016)... ... , ... When faced with having to use a toilet away from home ... body, and contamination of children when they use public toilets. This inspired her to ... people face. , The patent-pending SANI-POCKET enables a person to use a public toilet ...
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family Insurance, a Washington-based ... is initiating a charity drive to support the family of Cindy Hendrickson, a ... , On October 29th of this year, Cindy Hendrickson swerved to avoid ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... folded, pharmaceutical inserts and outserts. As a means of expanding capabilities Flottman ... will enable Flottman to individually code professional inserts (PIs) and patient package inserts ...
Breaking Medicine News(10 mins):